MERCK KGAA O.N./ DE0006599905 /
2024-04-25 10:50:03 AM | Chg. -1.500 | Volume | Bid10:54:47 AM | Ask10:54:47 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
150.300EUR | -0.99% | 170 Turnover: 25,635 |
150.300Bid Size: 267 | 150.300Ask Size: 267 | 19.45 bill.EUR | 1.46% | 23.19 |
GlobeNewswire
04-24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
04-24
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investiga...
GlobeNewswire
04-24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ...
GlobeNewswire
04-24
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASC...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA